Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced HER2+Breast Cancer × pertuzumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 34 HER2-positive Breast Cancer 3 Inflammatory Breast Neoplasms 2 Colonic Neoplasms 2 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Patient Preference 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Invasive Breast Cancer 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2+ Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1 Early or Locally Advanced HER2-positive Breast Cancer 1 Carcinoma, Ductal, Breast 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced HER2+Breast Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡